Form 4: Axogen Director John Johnson Reports Acquisition of Shares and Stock Options

Director John Johnson reports acquiring shares and stock options in Axogen, Inc. as part of an annual equity grant.

Summary

• On June 6, 2024, John Johnson, a director of Axogen, Inc., reported acquiring 10,653 shares of common stock.
• Following the transaction, Johnson directly owns 17,112 shares.
• Johnson also acquired 18,248 employee stock options with an exercise price of $7.04, exercisable from June 6, 2024, and expiring on June 6, 2034.
• These options represent the right to purchase 18,248 shares of common stock.
• The acquisition is part of an annual equity grant for service as a Director on the Axogen, Inc. Board of Directors.
• The equity grant is valued at $150,000 as of the grant date, with half in non-qualified stock options and half in restricted stock units, vesting on June 6, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which can be seen as a sign of confidence. However, it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future.
• The equity grant incentivizes the director to contribute to the company's success.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grant suggests a continued relationship between the director and the company.

Management Comments

• The annual equity grant for service as Director on the Axogen, Inc. Board of Directors is based on a $150,000 valuation as of the grant date.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and compliance with SEC regulations.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.
• The equity grant aligns the director's interests with those of the shareholders.

Key Dates